REDWOOD CITY, Calif.,
Nov. 20, 2014 /PRNewswire/
-- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty
pharmaceutical company focused on the development and
commercialization of innovative therapies for the treatment of
acute and breakthrough pain, today announced that senior management
will be participating at Piper Jaffray, RBC, Guggenheim and Roth
Healthcare Conferences. Details of the events are as follows:
Piper Jaffray Healthcare Conference 2014
Date: Tuesday, December
2nd
Location: New York, NY
Presentation Time: 2:30pm ET,
11:30am PT
RBC One on One Day 2014
Date: Thursday, December
4th
Location: Denver, CO
Roth Corporate Access Event 2014
Date: December 10
-12th
Location: Park City, UT
Guggenheim One on One Day 2014
Date: Tuesday, December
16th
Location: Boston, MA
The Piper Jaffray presentation will be webcast live and can be
accessed through the Investors page at www.acelrx.com. For
those not available to listen to the live broadcast, a replay will
be archived for 90 days and available through the Investors page on
www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on the development and commercialization of innovative therapies
for the treatment of acute and breakthrough pain. AcelRx's lead
product candidate, Zalviso, is designed to improve the management
of moderate-to-severe acute pain in adult patients in the hospital
setting by utilizing a high therapeutic index opioid, through a
non-invasive delivery route via a pre-programmed,
patient-controlled analgesia device. AcelRx has announced positive
results from each of the three completed Phase 3 clinical trials
for Zalviso, and has submitted an NDA to the FDA seeking approval
for Zalviso in the treatment of moderate-to-severe acute pain in
adult patients in the hospital setting and on July 25th, received a Complete Response Letter
from the FDA. AcelRx plans to initiate a Phase 3 clinical trial for
ARX-04, a product candidate for the treatment of moderate-to-severe
acute pain in a medically supervised setting. The Company has two
additional pain treatment product candidates, ARX-02 and ARX-03,
which have completed Phase 2 clinical development. For additional
information about AcelRx's clinical programs, please visit
www.acelrx.com.
Logo -
http://photos.prnewswire.com/prnh/20130226/MM67303LOGO
SOURCE AcelRx Pharmaceuticals, Inc.